75 results
8-K
EX-99.1
CTMX
CytomX Therapeutics Inc
8 May 24
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for
4:41pm
to continuing to explore the potential of this exciting agent in multiple EGFR positive cancers and to determining longer term strategy with our global
8-K
EX-99.1
CTMX
CytomX Therapeutics Inc
11 Mar 24
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
4:02pm
programs leverage validated oncology targets, potent effector mechanisms and tailored masking approaches. Our strategy is to address large oncology … to remain an important part of the Company’s strategy.
2024 Priorities and Key Milestones:
CX-904 (EGFRxCD3): Continued enrollment into Phase 1a
8-K
EX-99.1
0pp n0o5g
8 Aug 23
CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.1
ktq7cphr
9 May 23
CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:12pm
8-K
EX-99.1
c2qcm2iqm ru8ier
8 Nov 22
CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
4:09pm
8-K
sm1 f8n2ajdoa5dtwd
13 Jul 22
Cost Associated with Exit or Disposal Activities
4:10pm
424B5
2ltqsm 76dv5we0
4 Mar 22
Prospectus supplement for primary offering
5:22pm